Monopar Therapeutics : Patient in 520 mg/m2 cohort, previous

Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment


3 of 3 patients in the 520 mg/m2 cohort... | June 1, 2023

Related Keywords

Kimr Tsuchimoto , Monopartx Linkedin , Monopar Therapeutics Inc , Spanish Sarcoma Group Grupo Espa , Exchange Commission , Nasdaq , Twitter , Currently Enrolling Phase , Clinical Trial Design , Spanish Sarcoma Group , Grupo Espa , Private Securities Litigation Reform Act , Monopar Therapeutics Inc Stock Exchange , News , Information , Press Release , Patient , N , 20 , Reviously , Xperienced , Humor , Shrinkage , End , Sad , Nresected , Following , Camsirubicin , , F , Patients , The , 20 Mnpr Us61023l1089 ,